Skip to main content

Month: June 2020

ProQR Announces Expert Perspectives Conference Call Series

LEIDEN, Netherlands & CAMBRIDGE, Mass., June 12, 2020 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced that the Company will launch a series of Expert Perspectives calls to provide an in depth review of topics related to the Company’s pipeline and platform.The inaugural call in the series will be hosted on June 22, 2020 at 12pm EDT and will focus on Usher syndrome and retinitis pigmentosa, The call will feature a fireside chat between Aniz Girach, MD, Chief Medical Officer of ProQR Therapeutics, and Robert Koenekoop, MD, PhD of McGill University/Montreal Children’s Hospital. Drs. Girach and Koenekoop will also discuss QR-421a, ProQR’s investigational therapy for patients...

Continue reading

Karyopharm Presents XPOVIO® (selinexor) and Eltanexor Data at the European Hematology Association 2020 Virtual Annual Meeting

NEWTON, Mass., June 12, 2020 (GLOBE NEWSWIRE) — Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven  pharmaceutical company, today announced that eight posters relating to XPOVIO® (selinexor), the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, and eltanexor, its next generation SINE compound, will be presented at the European Hematology Association (EHA) 2020 Virtual Annual Meeting taking place June 11-21, 2020.The six selinexor abstracts include: (i) overall survival data from the Phase 2b SADAL study evaluating selinexor in patients with relapsed or refractory diffuse large-B-cell lymphoma (DLBCL) demonstrating a 9-month median overall survival in a patient population in which survival is expected to be

Continue reading

Pipestone Energy Corp. Announces it Has Successfully Maintained Its $225 Million Reserve Based Loan and Provides an Operations Update

CALGARY, Alberta, June 12, 2020 (GLOBE NEWSWIRE) — (PIPE – TSX-V) Pipestone Energy Corp. (“Pipestone Energy” or the “Company”) is pleased to announce that it has successfully redetermined its Reserve Based Loan (“RBL” or “Credit Facility”) with its syndicate of banks, maintaining its credit capacity of $225 million.RBL and Financial Liquidity Update:Pipestone Energy has closed on its RBL redetermination with its corporate banking syndicate, consisting of National Bank Financial Inc., Bank of Montreal, ATB Financial, and Canadian Western Bank. The Credit Facility’s capacity has been maintained at $225 million, of which the Company was drawn approximately $184 million as of June 12th, 2020. The Company’s previously announced $60 million capital program for 2020 is more than 95% complete, and with minimal capital expenditures forecast...

Continue reading

Imara Presents Positive Interim Results from Phase 2a Study of IMR-687 in Sickle Cell Disease at the Virtual European Hematology Association Annual Congress

Showed statistically significant increase in red blood cells containing fetal hemoglobin (F-cells) and dose-dependent increase in fetal hemoglobin percentage in high-dose group after 24 weeks of monotherapyIMR-687 was well tolerated as a monotherapy and in combination with hydroxyureaBOSTON, June 12, 2020 (GLOBE NEWSWIRE) — Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today presented interim results from its ongoing Phase 2a clinical trial of IMR-687 in adult patients with sickle cell disease (SCD) at the 25th European Hematology Association (EHA) Annual Congress.The data from this ongoing study demonstrated that IMR-687, an oral, once-a-day, potentially disease...

Continue reading

Vibe Announces Closing of Acquisition of Northern California Licensed Operating Cultivation Site and Planned Expansion of Cultivation Operations

SACRAMENTO, Calif., June 12, 2020 (GLOBE NEWSWIRE) — Vibe Bioscience Ltd. (CSE:VIBE)(OTC:VBSCF) (the “Company” or “Vibe”), a vertically integrated cannabis retailer and marijuana cultivator, is pleased to announce the closing of the acquisition of a 13,500 square foot operating cannabis cultivation facility in Crescent City, California and a phased plan to increase cultivation canopy by 40 per cent.“Vibe is very excited to complete the acquisition of this high-quality cultivation facility in Crescent City, California. This represents a unique and strategic opportunity for Vibe to add premium cultivation capacity to our existing Hype Cannabis Co. high-quality flower, distillate vape cartridges, and wax concentrates,” said Vibe CEO Mark Waldron. “Our planned expansion of the cultivation canopy by 40% will enhance Vibe’s...

Continue reading

Aptose Presents Early Phase 1a/b CG-806 Clinical Findings at the 25th Congress of the European Hematology Association

Safety, tolerability and phospho-BTK inhibition at first three CG-806 dose levels in patients with CLL and other B-cell malignanciesPlasma from CG-806 treated patients completely inhibited phospho-FLT3, suggesting current dose levels may be therapeutic in patients with AMLNew IND submitted to begin testing CG-806 in AML patientsSAN DIEGO and TORONTO, June 12, 2020 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that new clinical data on CG-806, its oral, first-in-class FLT3/BTK cluster selective kinase inhibitor, was presented in a poster presentation today at the 25th Congress of the European Hematology Association, EHA25 Virtual Congress.Early Clinical...

Continue reading

PINTEC to Report Full Year 2019 Financial Results on June 15, 2020

BEIJING, June 12, 2020 (GLOBE NEWSWIRE) — Pintec Technology Holdings Limited (NASDAQ: PT) (“PINTEC” or the “Company”), a leading independent technology platform enabling financial services in China, today announced that it will report its financial results for the full year of 2019 before the U.S. market opens on Monday, June 15, 2020. The earnings release will be available on the Company’s investor relations website at http://ir.pintec.com/.The Company’s management team will hold a Direct Event conference call on Monday, June 15, 2020, at 8:00 A.M. Eastern Time (or 8:00 P.M. Beijing Time on the same day) to discuss the financial results. Details for the conference call are as follows:Due to the global outbreak of the novel coronavirus, operator assisted conference calls are not available at the moment. All participants must...

Continue reading

Linda Mantia Joins Ceridian HCM Holding Inc. Board of Directors

TORONTO and MINNEAPOLIS, June 12, 2020 (GLOBE NEWSWIRE) — Ceridian (NYSE: CDAY; TSX: CDAY), a global human capital management (HCM) company, today announced that Linda Mantia has joined its Board of Directors and will serve on its Audit Committee.Ms. Mantia was Senior Executive Vice President, Chief Operating Officer of Manulife Financial Corporation, an international insurance and financial services company listed on the New York Stock Exchange (NYSE) and Toronto Stock Exchange (TSX).  Prior to joining Manulife, Ms. Mantia was Executive Vice President of Digital, Payments and Cards at Royal Bank of Canada (RBC), a multinational financial services company, also listed on the NYSE and TSX. Ms. Mantia held other leadership roles at RBC, including Executive Vice President, Global Cards and Payments. Before joining RBC, Ms. Mantia worked...

Continue reading

TG Therapeutics Announces Data Presentations at the 25th European Hematology Association (EHA) Annual Congress

NEW YORK, June 12, 2020 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations at the 25th European Hematology Association (EHA) annual congress including data from a Phase 1 study evaluating TG-1701, the Company’s once daily, selective, BTK inhibitor, as monotherapy and in combination with umbralisib and ublituximab (U2) in relapsed/refractory chronic lymphocytic leukemia (CLL) and lymphoma, as well as long term data from a Phase 1/1b study evaluating the combination of umbralisib and ibrutinib in relapsed/refractory CLL and mantle cell lymphoma (MCL).   Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer stated, “We have long been excited about the potential for dual BCR blockade by targeting both PI3K-delta and BTK in the treatment of hematologic malignancies, and...

Continue reading

Party City Announces First Quarter 2020 Financial Results

ELMSFORD, N.Y., June 12, 2020 (GLOBE NEWSWIRE) — Party City Holdco Inc. (the “Company” or “PRTY”; NYSE:PRTY) today announced financial results for the quarter ended March 31, 2020.Brad Weston, Chief Executive Officer, stated, “First and foremost, I want to express my deepest gratitude to our team members for their resilience in light of recent events affecting our country as well as the ongoing impact of the COVID-19 pandemic. Prior to the chain-wide store closures that were implemented in mid-March due to COVID-19, our first quarter results reflected sequential topline trend improvement. Our focus since then has been navigating the disruption created by the pandemic, with the health and safety of our team members and customers as our top priority. We instituted strict safety protocols across the Company and took steps swiftly and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.